S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor
cells from dividing so they stop growing or die.
PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with
unresectable benign meningioma.
Phase:
Phase 2
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Eastern Cooperative Oncology Group National Cancer Institute (NCI)